Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
NCT ID: NCT00702494
Last Updated: 2022-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
21 participants
INTERVENTIONAL
2008-06-30
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies
NCT04640246
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
NCT00052403
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors
NCT00005061
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
NCT00112229
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
NCT05120271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Multiple IV doses of TB-403, an antibody directed against PlGF
TB-403
Multiple IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TB-403
Multiple IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease
* Performance status 1 or less (ECOG)
Exclusion Criteria
* Concurrent second malignancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oxurion
INDUSTRY
BioInvent International AB
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ulrik Lassen, MD, PhD
Role: STUDY_CHAIR
Rigshospitalet, Denmark
Lena Winstedt, PhD
Role: STUDY_DIRECTOR
BioInvent International AB
Dorthe Nielsen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Herlev Hospital, Herlev, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Onkologisk Klinik 5072 Finsencentret Rigshospitalet
Copenhagen, , Denmark
Onkologisk Afdeling 54B1 Herlev Hospital
Herlev, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUDRACT No: 2008-001345-25
Identifier Type: -
Identifier Source: secondary_id
07-TB-403-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.